Immunological patterns identifying disease course and evolution in multiple sclerosis patients
Roberto Furlan(Vita-Salute San Raffaele University), Gianvito Martino(Vita-Salute San Raffaele University), Tomas Olsson(Karolinska University Hospital), Federica Agosta(Vita-Salute San Raffaele University), Elio Scarpini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), M. Gironi(Don Carlo Gnocchi Foundation), Mohsen Khademi(Karolinska University Hospital), Gıancarlo Comı(Casa di Cura Columbus), Antonio Uccelli(Istituti di Ricovero e Cura a Carattere Scientifico), Alessandra Bergami(San Raffaele University of Rome), Michela Deleidi(German Center for Neurodegenerative Diseases), Marco Rovaris(San Raffaele University of Rome), Filippo Martinelli Boneschi(Ollscoil na Gaillimhe – University of Galway), Diego Franciotta(Istituti di Ricovero e Cura a Carattere Scientifico), Massimo Filippi(Vita-Salute San Raffaele University), Aslı Kurne(San Raffaele University of Rome), Mauro Zaffaroni(Associazione Italiana Sclerosi Multipla)
Cited by 39
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
|New England Journal of Medicine|2010|2.2k
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
|New England Journal of Medicine|2016|2k